4 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 4 of 4 clinical reviews.
A deep-dive into the Heart Protection Study's primary and secondary endpoint results, effect sizes, confidence intervals, subgroup analyses, and time-course patterns for simvastatin 40 mg in high-risk patients.
Deep-dive into Heart Protection Study pre-specified and post-hoc subgroup analyses by age, sex, BMI, baseline LDL, diabetes status, and vascular history. Which high-risk patients benefited most from simvastatin 40 mg?
A plain-English deep dive into the Heart Protection Study (HPS), the largest statin RCT ever conducted, which proved simvastatin 40 mg cut major vascular events by 24% across a remarkably broad range of high-risk patients.
A clinical deep-dive into the methodological limitations, enrollment biases, generalizability gaps, and conflict-of-interest concerns surrounding the Heart Protection Study of simvastatin 40 mg.